Aesica Expands UK Development Capacity

Aesica Pharmaceuticals has doubled development capacity at its site in Queenborough, Kent, UK, giving it the capability to manufacture multiple drug products up to Phase III clinical trials.

The contract development and manufacturing organization (CDMO) said it can now develop and manufacture products from early formulation development through clinical production and into commercialization, offering a seamless end-to-end service to customers.

In January 2016, Aesica relocated its development and clinical manufacturing services from Nottingham to Queenborough as part of its strategy to align its service from a single source.

Aesica said the new center has also significantly extended its high potent and controlled drugs service. The site can handle potent drugs for any active up to SafeBridge category 3, together with controlled drugs, with licenses for both schedules 2 to 4. SafeBridge is a potency classification scheme for APIs, ranging from low (category 1) to high (category 4).

Ian Muir, Aesica’s managing director, said the additional capacity and services was a response to growing customer demand and part of its ongoing strategy to simplify the supply chain by combining its sources into a single location. He commented: “High potency is a key contract services market, with strong growth potential, requiring a mix of highly specialized and advanced technological skills and capabilities.”

Aesica said it still offers semi-solid development and inhalation services will continue with access to technology and knowhow, including metered dose inhalers and dry power inhalers provided by Bespak within the Consort Medical Group.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.